Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Paradigm Biopharmaceuticals Ltd ABN/ARBN Financial year ended: 94 169 346 963 30 June...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Application for quotation of securities - PAR
- 80% Safety Review Complete, September IA on Track
- June 2026 Quarterly Activities Report & Appendix 4C
- Paradigm Receives $5.75m R&D Tax Incentive Refund
- Drawdown of Tranche 4 under the Convertible Note Facility
Later from Paradigm Biopharmaceuticals
- Appendix 4E and 2026 Annual Report
- Melbourne Investor Lunch
- Notification regarding unquoted securities - PAR
- Notice under Section 708A
- Dr Daniel Furtner appointed Chief Medical Officer
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals